Travere Therapeutics (TVTX Quick QuoteTVTX - Free Report) reported $114.45 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 111.5%. EPS of -$0.14 for the same period compares to -$0.90 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $97.45 million, representing a surprise of +17.44%. The company delivered an EPS surprise of +50%, with the consensus EPS estimate being -$0.28.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Tiopronin products / Thiola: $22.96 million versus $21.58 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -8.4% change.
• Total net product sales: $94.84 million compared to the $83.91 million average estimate based on seven analysts.
• Revenue- FILSPARI: $71.89 million compared to the $62.72 million average estimate based on seven analysts. The reported number represents a change of +165% year over year.
• Revenue- License and collaboration revenue: $19.61 million versus $13.34 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +910.7% change.

View all Key Company Metrics for Travere here>>>

Shares of Travere have returned +9% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.